Hemp Inc (HEMP): BIG PHARMA FEARS HEMP & OTHER MED. MJ. C...

Rat Fink · 2013-08-13T01:41:40.0970000Z

BIG PHARMA FEARS HEMP & OTHER MED. MJ. COMPANIES WILL TAKE A BIG PORTION OF THE MEDICAL MARKET SHARE AWAY FROM THEM. THIS IS WHY, IMO, ONE OR SEVERAL BIG PHARMA COMPANIES ARE ATTEMPTING TO AGGRESSIVELY AND CONSTANTLY ATTEMPTING TO "SHOOT DOWN", IN WRITINGS, HEMP AND OTHER Medical Marijuana Industry companies/stocks. HOW are they TRYING TO "SHOOT DOWN" HEMP and other Medical Marijuana Industry Companies? The answer is "BEFORE YOUR VERY EYES"--IN WRITINGS WE READ. Could a Big Pharma company(s) be PAYING HEMP Bloggers to AGGRESSIVELY and CONSTANTLY write negative writings on HEMP to PUT HEMP and OTHER Medical Marijuana Industry companies OUT OF BUSINESS BEFORE THEY GROWS HUGE--AND TAKE MARKET SHARE AWAY FROM THEM. NOW can you see the BIG PICTURE??? MAKES SENSE doesn't it. BIG PHARMA WILL NOT and CANNOT SUCCEED--but THEY WILL KEEP TRYING TO STOP HEMP and OTHER Medical Marijuana Industry stocks VIA DAILY WRITINGS! The Medical Marijuana Industry is GROWING EXPONENTIALLY as MORE and MORE U. S. States are LAXING their Medical Marijuana/CBD/HEMP laws--20 U.S. States NOW ALLOW Medical Marijuana to be used in their states. Fellow HEMP investors, QUESTION the CREDIBILITY of and THINK ABOUT the “HIDDEN MOTIVES” of ANYONE ATTEMPTING to PERSISTENTLY and FREQUENTLY, via DAILY WRITINGS, to "SHOOT DOWN" HEMP. HEMP WILL BE HUGE IN THE FUTURE Those who BUY HEMP NOW are PRUDENT--as those who did BEFORE THE BIG POP UP on 8/9/13!!!

Play Episode

6min

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Oriole Resources wraps up pivotal 2024, targets major gold milestones in 2025

Oriole Resources PLC (AIM:ORR) CEO Martin Rosser and CFO Bob Smeeton take Proactive's Stephen Gunnion through the company’s latest full-year results and upcoming milestones across its key exploration projects. Rosser highlighted a pivotal year for the company’s Bibemi and Mbe gold projects in Cameroon. At Bibemi, a recently completed phase five drilling campaign is feeding into a revised Mineral Resource Estimate (MRE), expected this quarter. “We believe there's very good potential to not just increase the amount of gold, but also improve the category of the resource,” said Rosser. The company is also advancing an exploitation license application for the project. At Mbe, maiden drilling continues, following trenching results that indicated strong mineralisation. “We think Mbe South has significant potential to host a substantial gold deposit,” Rosser added. Smeeton detailed a £2 million reduction in operating loss and financial support from BCM International. “Since year-end, BCM have given us $1.1 million, largely replenishing CapEx,” Smeeton noted. He also confirmed progress on a joint venture agreement with Managem at the Senala project in Senegal. Rosser pointed to potential sector-wide revaluations driven by high gold prices and possible M&A activity. “Oriole’s shares are significantly undervalued,” he said. For more updates from Oriole Resources and other mining sector interviews, give this video a like, subscribe to Proactive’s YouTube channel, and enable notifications so you don’t miss future content. #OrioleResources #GoldExploration #CameroonMining #MbeProject #BibemiGold #JuniorMiners #MiningInvestment #MineralResourceEstimate #GoldPrice #MiningFinance #ProactiveInvestors #ManagemJV #SenalaProject #CameroonGold #ExplorationDrilling

Proactive - Interviews for investors

Data security: archTIS lands key licensing deal

archTIS Ltd CEO and Managing Director Daniel Lai talked with Proactive about a newly signed $390,000 licensing agreement with a major Japanese multinational. The deal builds on archTIS’s acquisition of Direktiv and its integration of advanced cybersecurity technology into its Trusted Data Integration platform. Lai explained that the licensing agreement enables the Japanese company—an asset services provider with operations valued at $12.5 billion—to introduce new data-centric security services into the Japanese market. “This is just another example of that occurring, which is really exciting for the company,” Lai said, referring to archTIS’s broader international expansion strategy. He noted that the company had always planned to replicate its success with the Australian Department of Defence and local defence industrial base in overseas markets, particularly those facing geopolitical pressures. Lai also highlighted progress in the US and Europe, where trials were recently completed with a large US department and NATO in the UK. Looking ahead, he remained “quietly optimistic” about meeting financial targets by June 30 and delivering further material updates to the market. He acknowledged market timing and election cycles as influencing deal flow, but said government and intelligence agency engagement continues to build momentum. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe, and turn on notifications for future content. #archTIS #Cybersecurity #DataSecurity #LicensingDeal #JapaneseMarket #QuadAlliance #TrustedDataIntegration #GlobalExpansion #DefenseTechnology #ProactiveInvestors

Proactive - Interviews for investors

European defense spending boom: Key investment opportunities amid global shifts

Jane Edmondson, Head of Index Product Strategy at TMXVettaFi, joined Steve Darling from Proactive to discuss the rapidly evolving global defense landscape and its investment implications. With geopolitical tensions on the rise and shifting defense priorities, investors must navigate new opportunities and risks in the sector. Edmondson highlighted Europe's unprecedented surge in defense spending, a direct response to the U.S. decision to scale back military aid to Ukraine. Central to this shift is the European Union’s €800 billion "Rearm Europe Readiness 2030" initiative, aimed at bolstering military preparedness. This includes substantial investments across key defense technologies and a dedicated €150 billion credit facility to enhance military capabilities. “There’s going to be a lot of spending to come,” Edmondson noted, emphasizing major growth areas such as artificial intelligence, cyber defense, drone technology, and advanced artillery systems. She pointed out that leading European defense firms—including Rheinmetall, BAE Systems, Thales, Dassault, and Leonardo SPA—stand to benefit significantly from this expansion. Additionally, South Korea’s Hanwha Aerospace is emerging as a key player in global defense contracts. In contrast, U.S. defense companies are experiencing headwinds due to budget cuts and canceled procurement deals, leading to a relative downturn in the sector. Another critical shift in global defense procurement is unfolding as traditional U.S. allies reconsider their defense purchases. Canada and Portugal, for instance, are re-evaluating orders for U.S.-made F-35 fighter jets in favor of alternative options, such as aircraft from Dassault Aviation. Edmondson stressed that these geopolitical realignments are creating strong economic tailwinds, particularly for Germany, which is set to invest an estimated €500 billion in defense over the next several years. She cited a recent Goldman Sachs report, which projects that half of this spending will

Followers	291
Posts	76118
Boards Moderated	3
Alias Born	03/20/2013

Volume:	1,965,666
Day Range:	0.000001 - 0.000001
Bid:
Ask:
Last Trade Time:	3:49:46 PM EDT
Total Trades:	7

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

HEMP Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free